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The CC-chemokine receptor 5 (CCR5) is the major coreceptor for macrophage-tropic (R5) HIV-1 strains. Several small molecule inhibitors of
CCR5 that block chemokine binding and HIV-1 entry are being evaluated as drug candidates. Here we define how CCR5 antagonists TAK-779,
AD101 (SCH-350581) and SCH-C (SCH-351125), which inhibit HIV-1 entry, interact with CCR5. Using a mutagenesis approach in combination
with a viral entry assay to provide a direct functional read out, we tested predictions based on a homology model of CCR5 and analyzed the
functions of more than 30 amino acid residues. We find that a key set of aromatic and aliphatic residues serves as a hydrophobic core for the ligand
binding pocket, while E283 is critical for high affinity interaction, most likely by acting as the counterion for a positively charged nitrogen atom
common to all three inhibitors. These results provide a structural basis for understanding how specific antagonists interact with CCR5, and may be
useful for the rational design of new, improved CCR5 ligands.
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HIV-1 cellular entry inhibitors are a promising new class of
potential anti-HIV-1/AIDS drugs (Michael and Moore, 1999;
Moore and Stevenson, 2000; LaBranche et al., 2001; De Clercq,
2002). By interacting with the viral envelope glycoproteins
(gp120 or gp41), with CD4 or with the coreceptors, these
inhibitors block different steps in the complex sequence of
events leading to virus–cell fusion (Michael and Moore, 1999;⁎ Corresponding author. Box 187, Rockefeller University, 1230 York Ave.,
New York, NY 10021, USA. Fax: +1 212 327 7904.
E-mail address: seiberc@mail.rockefeller.edu (C. Seibert).
1 Present affiliation: Avance Pharma Inc., Laval, Quebec, Canada H7V 5B7.
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.01.018Moore and Stevenson, 2000; LaBranche et al., 2001; De Clercq,
2002). The HIV-1 coreceptors are particularly attractive targets
for entry inhibitors, because they belong to the protein
superfamily of G protein-coupled receptors (GPCRs) (Schwarz
and Wells, 2002; Kazmierski et al., 2003; Horuk, 2003; Seibert
and Sakmar, 2004).
Although several chemokine receptors are able to mediate
HIV-1 entry in vitro, only CCR5 and CXCR4 are likely to be
of major importance in vivo and hence relevant targets for
pharmaceutical intervention (Zhang and Moore, 1999; Zhang
et al., 2000). CCR5 in particular is the principal coreceptor
for the HIV-1 strains that are most commonly transmitted
between individuals and which predominate during the early
years of infection (Berger et al., 1999; Douek et al., 2003).
The clinical relevance of the predominant use of CCR5 by
Fig. 2. CCR5 residues involved in the interaction with TAK-779, AD101 or
SCH-C. The seven transmembrane helices (H1–H7) and helix 8 (H8) are
symbolized as cylinders. The assignment of the helical segments is based on the
transmembrane topology of rhodopsin (Palczewski et al., 2000). Extracellular
and cytoplasmic loops are labeled E1, E2, E3 and C1, C2, C3, respectively. The
amino acid sequence is represented in single-letter code (excluding the C-
terminal hemagglutinin affinity tag). Residues highlighted in red have been
shown to be required for efficient interaction with TAK-779, AD101 and SCH-
C; residues labeled in yellow have been shown to be required for a subset of
these inhibitors only (A29, R31 for TAK-779; F79 for AD101; D76, F113 for
AD101 and SCH-C; Y108 for TAK-779 and AD101).
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CCR5 mutation, CCR5-Δ32, that generates a non-functional
coreceptor (Berger et al., 1999; Liu et al., 1996; Samson et
al., 1996; Dean et al., 1996; Wu et al., 1997; O'Brien and
Moore, 2000). Individuals who are homozygous for this
mutation are strongly protected against HIV-1 infection, while
infected, heterozygous individuals progress less rapidly to
disease and death. Furthermore, no obvious adverse effects on
health have been observed in individuals lacking functional
CCR5.
Several different types of inhibitors for CCR5-mediated
HIV-1 entry have now been identified and are in pre-clinical or
clinical development as drug candidates. These include CC-
chemokine derivatives, anti-CCR5 monoclonal antibodies and
small molecule receptor antagonists (Michael and Moore, 1999;
Moore and Stevenson, 2000; LaBranche et al., 2001; De Clercq,
2002; Schwarz and Wells, 2002; O'Hara and Olson, 2002;
Kazmierski et al., 2003; Horuk, 2003). High-throughput
screening of compound libraries followed by medicinal
chemistry-based optimization of lead structures allowed the
discovery of several potent, small molecule antagonists of
CCR5-mediated chemokine signaling and HIV-1 entry
(Schwarz and Wells, 2002; Kazmierski et al., 2003; Horuk,
2003; Seibert and Sakmar, 2004). TAK-779, a quaternary
ammonium anilide (Fig. 1), was the first small molecule CCR5
antagonist reported (Baba et al., 1999). Other small molecule
CCR5 antagonists with improved potency and/or pharmaco-
logical properties have since been described (Schwarz andFig. 1. Chemical structures of TAK-779, AD101 and SCH-C. TAK-779, a
quaternary ammonium ion, is shown with a chloride counterion. AD101 and
SCH-C are shown in the protonated state that predominates at physiological pH.
In each structure, the positively charged nitrogen atom is highlighted in bold. On
the basis of pKa prediction methods (Perrin et al., 1981), we estimated that the
second nitrogen atom in the AD101 piperazine ring is not protonated at
physiological pH.Wells, 2002; Kazmierski et al., 2003; Horuk, 2003; Seibert and
Sakmar, 2004). For example, SCH-C (SCH-351125) is an
oximino-piperidino-piperidine amide (Fig. 1) (Palani et al.,
2001, 2002; Strizki et al., 2001) that has antiviral activity in
HIV-1-infected humans (Reynes et al., 2002). AD101 (SCH-
350581) (Fig. 1), a piperidino-piperazine based compound, is
about 10-fold more potent than SCH-C but has poor
pharmacological properties (Tagat et al., 2001a, 2001b). SCH-
D (SCH-417690), which is now in clinical development but was
not available when this study was conducted, is structurally
related to AD101 and has both improved potency and better
pharmacological properties compared to SCH-C (Tagat et al.,
2004; Schurmann et al., 2004).
TAK-779, SCH-C and AD101 all inhibit HIV-1 entry into
target cells by blocking the interaction between the gp120/CD4
complex and CCR5 (Dragic et al., 2000; Tsamis et al., 2003).
The underlying molecular mechanism of this activity is not
known. Available evidence from mutagenesis and immunolog-
ical studies suggests that the gp120 binding site on CCR5 is
located within its N-terminus (Nt) and the second extracellular
loop (E2) (Rucker et al., 1996; Ross et al., 1998; Blanpain et al.,
1999; Howard et al., 1999; Dragic, 2001; Dragic et al., 1998;
Rabut et al., 1998; Farzan et al., 1998; Doranz et al., 1997). The
TAK-779, AD101 and SCH-C molecules, however, are
believed to bind predominantly within the transmembrane
domain of CCR5 (Dragic et al., 2000; Tsamis et al., 2003).
Several CCR5 residues required for these compounds to inhibit
HIV-1 entry have been identified using alanine scanning
mutagenesis (Fig. 2) (Dragic et al., 2000; Tsamis et al., 2003).
However, a detailed side-by-side comparison of several
Table 1
Effects of substitutions of CCR5 residues on inhibition of HIV-1 entry
Mutant a % HIV-1 JR-FL entry b
TAK-779 AD101 SCH-C
WT-CCR5 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
A29L 73.5 ± 10.1 0.6 ± 1.9 0.0 ± 0.0
L33A 40.0c 34.2 ± 2.2d 19.9 ± 2.7d
L33V 30.2 ± 6.8 6.3 ± 0.9 15.1 ± 0.6
L33I 25.3 ± 5.3 5.3 ± 2.9 6.0 ± 5.3
L33N 68.5 ± 8.4 24.0 ± 3.3 41.8 ± 3.3
L33T 59.0 ± 5.4 43.0 ± 6.8 63.5 ± 3.5
L33M 27.3 ± 3.2 21.3 ± 5.7 40.3 ± 5.9
Y37A 74.0c 71.5 ± 2.2d 32.1 ± 5.5d
Y37F 43.5 ± 9.8 0.0 ± 0.0 0.8 ± 0.8
Y37W 60.3 ± 1.4 3.7 ± 2.2 0.0 ± 0.0
Y37W/W86Y 77.6 ± 13.0 48.8 ± 3.2 57.3 ± 6.3
D76A 1.0c 44.7 ± 5.1d 20.6 ± 3.3d
D76E 4.8 ± 2.8 8.3 ± 5.3 22.0 ± 2.7
D76K 4.6 ± 3.5 34.6 ± 8.5 68.2 ± 19.6
V83A 18.8 ± 3.6 18.6 ± 2.5 21.1 ± 0.1
W86A 79.0c 93.8 ± 12.4d 62.0 ± 0.8d
W86F 56.3 ± 4.2 39.8 ± 8.9 51.7 ± 5.4
W86Y 60.3 ± 5.3 42.2 ± 4.0 74.5 ± 4.2
A90L 36.1 ± 6.0 43.1 ± 4.3 61.0 ± 7.1
L104E/E283L 71.4 ± 4.9 97.2 ± 4.8 77.4 ± 11.7
Y108A 100.0c 42.6 ± 1.0d 9.6 ± 0.2d
Y108F 78.5 ± 2.1 24.2 ± 2.6 8.5 ± 1.4
Y108Q 33.3 ± 6.3 39.6 ± 2.4 11.3 ± 0.6
E283A 27.0c 118.7 ± 18.4d 94.6 ± 13.3d
E283Q 28.1 ± 4.3 61.7 ± 4.9 122.6 ± 22.8
E283L 84.7 ± 1.3 73.1 ± 3.6 90.4 ± 11.1
E283D 39.8 ± 4.4 98.5 ± 11.0 73.7 ± 5.3
E283K 81.0 ± 10.5 106.7 ± 13.2 87.5 ± 11.2
G286A 48.1 ± 2.8 2.7 ± 0.2 3.4 ± 1.6
G286V 61.6 ± 9.4 65.9 ± 9.4 66.9 ± 12.3
a The following mutations in CCR5 had no significant effect on HIV-1 entry
in the presence of any of the three inhibitors: D2K, Y3K, Y10K, D11K, Y14K,
Y15F, Y15D, Y15K, E18K, N24Q, A30L, V40A, V40I, D76N, V83I, V83L,
V83T, A91L, A92L, A92V, D95N, D95K, L104E, E172K, N192K, E262K,
N268D, S270L, S271L, D276N, D276L, D276K, A278L.
b Relative HIV-1 entry in the presence of inhibitors normalized to entry in the
absence of inhibitors. All values are means ± standard error of at least three
independent experiments. A value of 100% means that a mutant is insensitive to
the inhibitor, a value of 0% means that a mutant is as sensitive to the inhibitor as
wild-type CCR5.
c Data from Dragic et al. (2000).
d Data from Tsamis et al. (2003).
43C. Seibert et al. / Virology 349 (2006) 41–54inhibitors with the aim of identifying their mechanism of action
has not been reported.
We hypothesized that common structural elements among
the inhibitors interact with a common ligand binding pocket in
the transmembrane domain of CCR5, while other compound-
specific elements provide additional receptor contacts (Tsamis
et al., 2003). To test this hypothesis, we constructed a three-
dimensional model of the transmembrane domain of CCR5
based on the rhodopsin crystal structure (Palczewski et al.,
2000). We used this model to analyze data from previous
mapping studies (Dragic et al., 2000; Tsamis et al., 2003), and to
design a series of receptor mutants, which were tested for
inhibitor sensitivity in an HIV-1 entry assay. The results confirm
the fidelity of the model of CCR5 topology and support the
hypothesis of a common inhibitor-binding site. Furthermore,
the specific contributions of key residues involved in a direct
interaction between CCR5 and each of the three small molecule
inhibitors were defined, and largely account for differences in
their potency and specificity. These results provide a structural
basis for understanding how small molecules antagonize HIV-1
entry via CCR5, and may be useful for the rational design of
more effective inhibitors.
Results
The role of CCR5 extracellular domain residues
The TAK-779, AD101 and SCH-C structures contain
hydrophobic aromatic groups as well as more hydrophilic
regions that include a positively charged nitrogen atom (Fig. 1).
While TAK-779, a quaternary ammonium ion, has a permanent
positive charge, AD101 and SCH-C respectively possess basic
piperazine or piperidine nitrogens that are protonated at
physiological pH (Perrin et al., 1981). Our initial hypothesis
was that the hydrophobic parts of TAK-779, AD101 and SCH-C
might bind to the transmembrane domain of CCR5 while the
more hydrophilic regions, including the positively charged
nitrogen, would interact with the extracellular domain.
However, this hypothesis was not supported by the results of
an extensive alanine scanning mutagenesis screen of the entire
extracellular domain of CCR5 (Dragic et al., 2000; Tsamis et al.,
2003). We designed and tested additional mutants to determine
whether the contribution of residues in the N-terminus (Nt) or
the extracellular loops (E1, E2 and E3) might have escaped
detection by the alanine mutagenesis approach (see legend to
Table 1).
We first investigated whether any of the acidic residues D2
(Nt), D11 (Nt), E18 (Nt), D95 (E1), E172 (E2), E262 (E3),
D276 (E3) or the tyrosine residues Y3 (Nt), Y10 (Nt), Y14 (Nt)
and Y15 (Nt) that are potentially sulfated (Farzan et al., 1999;
Seibert et al., 2002) (see Fig. 2), could be involved in the
interaction with the positively charged nitrogen that is common
to TAK-779, AD101 and SCH-C (Fig. 1). We changed each of
these residues to lysine. Also, we tested other non-alanine
mutants that involve a significant change in either the size or
charge of the side chain (see legend to Table 1). When assayed
for inhibition of HIV-1 entry, none of these mutants differedsignificantly from wild-type CCR5 for any of the three
inhibitors (see legend to Table 1). In accordance with our
previous studies (Dragic et al., 2000; Tsamis et al., 2003), we
find no evidence that TAK-779, AD101 or SCH-C interacts
with extracellular regions of CCR5. In particular, there are no
ionic interactions between acidic residues in the CCR5
extracellular domain and the positively charged nitrogen
atoms of the antagonists.
Structural model of the CCR5 transmembrane domain
Next, we focused on defining the specific function of
transmembrane domain residues in the interaction of CCR5
with TAK-779, AD101 and SCH-C. We previously used a low
resolution rhodopsin model (Shieh et al., 1997), derived from
44 C. Seibert et al. / Virology 349 (2006) 41–54electron diffraction and NMR studies, as a template to construct
a model of the CCR5 transmembrane domain that was useful for
mapping the TAK-779 binding site (Dragic et al., 2000). Here,
we prepared an improved model of CCR5 based on the crystal
structure of rhodopsin, which was solved at 2.8 Å resolution
(Palczewski et al., 2000). This CCR5 model includes the seven
α-helical transmembrane segments H1 (K26-C58), H2 (S63-
W94), H3 (F96-V131), H4 (T141-I165), H5 (W190-I217), H6
(K228-Q261) and H7 (L275-G301). Not included are the N-
and C-terminus (Nt, Ct), the extracellular and cytoplasmic loop
regions (E1–E3, C1–C3) and the putative helix 8 (H8). The
new model redefines the assignments of the transmembrane
helices. Furthermore, the relative orientations of the helices and
the positions of the amino acid side chains are also significantly
different compared to the previous model. The new model
proved to be generally more reliable in predicting and
explaining the results from our mutagenesis studies than the
previous model (see below). The model is depicted in Fig. 3,
which also presents information on the inhibitor-binding site
that was derived from the experiments described below. The
model coordinates are available upon request.Fig. 3. Model of the transmembrane domain of CCR5 with energy-minimized structu
779, AD101 and SCH-C in space-filling and stick representation. Atoms are color-co
bromine, brown. Note the similarities between the three structures: The molecules ad
groups (facing downwards), the right part contains a positively charged nitrogen ato
viewed from within the plane of the membrane. The extracellular surface is oriented
seven α-helical transmembrane segments (H1–H7, Cα-traces only) are depicted as
CCR5 with TAK-779, AD101 or SCH-C are shown in stick representation. The color
colored residues (L33, Y37, W86, A90, I198, E283, G286) affected TAK-779, AD101
these inhibitors only (A29, R31: TAK-779; F79: AD101; D76, F113: AD101 and S
extracellular side of the membrane after rotating the model by approximately 90° out
the same as in panel B. The models in panels A, B and C are shown at the same scThe CCR5 binding pocket for small molecule inhibitors
To localize the small molecule binding site on CCR5, we
first reanalyzed data from our previous mapping studies
(Dragic et al., 2000; Tsamis et al., 2003) (Fig. 2) using the
refined CCR5 model (Fig. 3). For completeness, we included
information on residues A29, V83, A90 and G286 in the
analysis although these residues were only identified later in
this study. While amino acid substitutions of residues L33,
Y37, V83, W86, A90, I198, E283 and G286 reduced the
inhibitory effect of all three compounds in an HIV-1 entry
assay, certain changes at other residues had a more specific
effect (Fig. 2). For example, substitutions of D76 and F113
adversely influenced the inhibitory activities of AD101 and
SCH-C, but not of TAK-779. Likewise, changing residue
Y108 affected the activity of TAK-779 and AD101, but not of
SCH-C. Only TAK-779 activity was sensitive to alterations at
residues A29, R31 and T82, and only AD101 was affected by
substitutions of F79.
The majority of the residues important for the interactions
of CCR5 with TAK-779, AD101 and/or SCH-C are clusteredres of TAK-779, AD101 and SCH-C. (A) Energy-minimized structures of TAK-
ded: carbon, green; oxygen, red; nitrogen, blue; hydrogen, grey; fluorine, black;
opt a broadly similar L-shape, the left segment consists of hydrophobic aromatic
m (arrow mark). (B) Structural model of the transmembrane domain of CCR5
towards the top of the figure, the cytoplasmic surface towards the bottom. The
blue-colored ribbons. Amino acid residues required for efficient interaction of
coding scheme is the same as in Fig. 2: substitution by alanine (or leucine) of red-
and SCH-C activity, replacement of yellow-colored residues affected a subset of
CH-C; Y108: TAK-779 and AD101). (C) View of the CCR5 model from the
of the paper plane from the orientation in panel B. Labeling and color coding are
ale.
Fig. 4. Orientation of key acidic and aromatic residues in the small molecule
binding site. Close-up view on the putative binding site from within the plane of
the membrane showing the Cα-traces of transmembrane helices H1, H2, H3 and
H7 (blue-colored tubes). The extracellular surface is oriented towards the top of
the figure, the cytoplasmic surface towards the bottom. Key residues E283, Y37,
W86 and Y108 are colored in grey, G286 is shown in red, D76 is colored in
yellow and L104 is depicted in green. Side chain oxygen atoms are labeled in
red, and side chain nitrogen atoms are labeled in blue.
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distance from the extracellular border to about one-third of
the way into the transmembrane domain and surround a
cavity that is believed to be the small molecule binding
pocket (Figs. 3B, C). According to the CCR5 model, residues
V83, W86, A90, Y108 and E283 point toward the center of
the helical bundle (Fig. 3C). These residues are, therefore,
particularly good candidates for a direct interaction with the
small molecule inhibitors. Residues A29, L33 and Y37 are
also located inside the helical bundle but tend to be oriented
towards the cleft between transmembrane helices H1 and H7
(Fig. 3C). Hence, this cleft might also participate in inhibitor
binding. Residue G286 on the other hand is roughly oriented
towards H3 and H6.
To gain insight into how TAK-779, AD101 and SCH-C
might fit into this putative binding pocket, we calculated their
energy-minimized structures. All three inhibitors most likely
adopt a broadly similar, bent conformation (Fig. 3A). In the
case of TAK-779, the calculated structure was confirmed to
be accurate by using NMR spectroscopy (data not shown).
Juxtaposing the models for CCR5 (Figs. 3B, C) and the small
molecules (Fig. 3A) suggests that several of the residues that
were previously identified by alanine-scanning mutagenesis
might not interact directly with the inhibitors. In particular,
the side chains of residues R31, D76, F79, T82, F113 and
I198 are either located outside the helical bundle or are likely
to be too distant from the putative binding pocket. Due to the
inherent limitations of the CCR5 homology model and
because the specific receptor and inhibitor conformations in
the complex are currently not known, we do not present any
computational docking studies.
The role of E283 and D76
Our observation that none of the negatively charged residues
in the extracellular domain of CCR5 is involved in the
interaction with the cationic small molecule inhibitors (Table
1) focused our attention on acidic residues in the transmembrane
domain of the receptor. Alanine scanning mutagenesis of the
transmembrane domain identified two acidic residues, E283 and
D76 (Dragic et al., 2000; Tsamis et al., 2003). Of these residues,
only E283 in H7 is critical for CCR5 to interact efficiently with
TAK-779, AD101 and SCH-C. Substitution of D76 in H2, on
the other hand, affects the activity of AD101 and to a lesser
extent SCH-C, but not TAK-779. According to the CCR5
model, the carboxyl group of residue E283 is located in the
putative binding pocket and is hence well positioned to serve as
the counterion for the charged nitrogen atom on each inhibitor
(Fig. 4). Importantly, E283 is not surface accessible and does
not have an apparent positive counterion in the CCR5 model.
E283 is predicted to be protonated and hydrogen bonded to
Y37. The absence of a positive counterion in the vicinity of
E283 in CCR5 should facilitate an ionic interaction with the
positively charged inhibitors. A direct interaction between D76
and the small molecules is less likely to occur, however, because
this residue is located in the center of the transmembrane
domain (Fig. 4). Moreover, D76 is located in a polar pocket andpart of a hydrogen-bonding network that includes N48, H289
and C290.
To clarify the role of E283 and D76 in small molecule
inhibition of HIV-1 entry, we introduced non-alanine substitu-
tions at both positions (Table 1). Replacing E283 with
glutamine reduced the ability of each of the three compounds
to inhibit HIV-1 entry, the effect being more pronounced for
AD101 and SCH-C than for TAK-779 (Table 1). For AD101
and SCH-C, the effect of the E283L substitution was not
significantly different from that seen with E283A and E283Q
(Table 1). However, the E283L substitution was more effective
than either E283A or E283Q at impairing the inhibitory activity
of TAK-779 (Table 1). This difference between AD101/SCH-C
and TAK-779 might be caused by steric interference between
TAK-779 and a leucine side chain at residue 283.
These results indicate that a negative charge at position 283
is required for efficient interaction of CCR5 with the small
molecule inhibitors, most likely by acting as a counterion for the
positively charged nitrogen atom. Substituting E283 with a
positively charged lysine residue not surprisingly caused a
strong reduction in inhibitory activity for TAK-779, AD101 and
SCH-C (Table 1). However, the conservative substitution of
E283 with an aspartate residue (E283D) created a coreceptor
with properties similar to those of the E283A and E283Q
mutants (Table 1). This result suggests that the shorter alkyl
chain of aspartate compared to glutamate prevents the aspartate
carboxyl group from protruding far enough into the binding
pocket to interact efficiently with the inhibitors, or otherwise
positions the carboxyl group inappropriately. To probe further
the role of E283, we swapped the position of the glutamate side
chain of residue E283, by creating the L104E/E283L double
mutant. According to the CCR5 model, the side chain of residue
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E283 (Fig. 4). The L104E substitution did not itself affect HIV-
1 entry inhibition by TAK-779, AD101 or SCH-C, so an
additional acidic residue can be tolerated within the binding
pocket. However, the L104E/E283L double mutant behaved
similarly to the E283L mutant, and differently from the L104E
mutant, in that it was only weakly sensitive to the three
inhibitors (Table 1).
In contrast to what was observed for E283, replacement of
D76 with asparagine resulted in a coreceptor with wild-type
CCR5 characteristics (Table 1). This clearly shows that a
negative charge on the side chain of D76 is not required for
the interaction with the antagonists. However, replacement of
D76 with glutamate led to a loss in sensitivity towards SCH-
C only, while its replacement with lysine reduced sensitivity
to AD101 and SCH-C but not TAK-779 (Table 1). These
results suggest that a hydrogen acceptor/donor group at
residue 76 is required for the efficient interaction with AD101
and SCH-C but not TAK-779. We cannot rule out completely
that D76 might interact directly with functional groups in
AD101/SCH-C. However, because of the unfavorable location
of D76 for such an interaction (Fig. 4), it is more likely that a
hydrogen bond between D76 and another CCR5 residue is
responsible for the observed effects. As noted above, D76 in
H1 is predicted to interact with both N48 in H2 and H289/
C290 in H7. Disrupting this hydrogen-bonding network in the
D76A and D76K mutants would likely change the position or
orientation of H1, H2 or H7.
Interaction of inhibitors with key CCR5 aromatic residues
The CCR5 model predicts that the aromatic rings of Y37 and
W86 constitute a large area of the small molecule binding
interface. Furthermore, they are located in close proximity to the
carboxyl group of E283 (Fig. 4). Another aromatic residue,
Y108, is located directly below these residues with its hydroxyl
group pointing towards the center of the helical bundle (Fig. 4).
Substituting Y108 with alanine significantly reduced the
inhibitory activity of TAK-779 and AD101, but not of SCH-C
(Dragic et al., 2000; Tsamis et al., 2003) (Table 1), which is
surprising because AD101 is structurally related to SCH-C but
not TAK-779 (Fig. 1).
To define the specific, individual contributions of residues
Y37, W86 and Y108 to the interaction of the inhibitors with
CCR5, we first addressed whether it was the hydroxyl group or
the aromatic moiety of tyrosine residue Y37 that was the more
important. The Y37F mutant remained sensitive to AD101 and
SCH-C (Table 1), so the aromatic ring but not the hydroxyl
group of Y37 must be involved in interacting with these
inhibitors. To further define the side-chain requirements for
Y37, we made a tryptophan substitution. The Y37W mutant
remained fully sensitive to both AD101 and SCH-C (Table 1).
However, TAK-779 sensitivity was severely reduced by the loss
of the phenolic hydroxyl group in both the Y37F and Y37W
mutants (Table 1), suggesting that the hydroxyl group might be
involved in a specific interaction with the TAK-779 molecule.
Alternatively, the hydroxyl group could participate in anintramolecular interaction within CCR5 that might be required
for binding TAK-779, but not AD101 or SCH-C.
Next, we replaced W86 with phenylalanine or tyrosine. The
CCR5 model predicts that the smaller aromatic side-chain of
these residues will not reach very deeply into the inhibitor-
binding pocket, but will instead point towards H1 (Fig. 4). The
HIV-1 entry inhibition experiments support this prediction
(Table 1). Thus, the W86F and W86Y mutant coreceptors are
relatively insensitive to the three compounds, indicating that
phenylalanine and tyrosine cannot fully replace W86 in the
binding pocket. Moreover, HIV-1 entry data for the Y37W/
W86Y double mutant indicate that the mere presence of an
indole ring system is not sufficient; its precise location within
the binding pocket is also crucial. The inhibitor sensitivity of the
Y37W/W86Y mutant coreceptor resembles that of the W86Y
mutant (Table 1), so swapping the positions of these two key
aromatic residues does not permit CCR5 to interact properly
with any of the inhibitors.
We then analyzed the side-chain requirements for residue
Y108. The inhibitor-selective effect of the tyrosine to
phenylalanine substitution, Y108F, implies that the phenolic
hydroxyl group is important for CCR5 to interact with TAK-
779, less critical for AD101 and not required at all for SCH-C
(Table 1). However, when a hydrogen-bond acceptor/donor
group was retained on a non-aromatic residue at position 108,
by replacing the hydroxyl group with an amide to make the
Y108Q mutant, CCR5 remained fully sensitive to SCH-C but
not to either TAK-779 or AD101 (Table 1). Thus, the aromatic
moiety of Y108 might also be involved in the interaction of
CCR5 with TAK-779 and AD101. This could be a direct effect
or, more likely, an indirect one, for example by affecting the
precise positioning of the hydroxyl group.
The role of aliphatic amino acid residues
We next addressed the role that certain aliphatic amino acid
residues play in the interaction of CCR5 with TAK-779,
AD101 and SCH-C. According to the CCR5 model, several
small aliphatic side chains are located at the extracellular border
of transmembrane helices H1, H2, H3 and H7 (Fig. 5)—a
region predicted to be the entrance of the binding pocket. A29
and A30 in H1 are oriented not towards the binding pocket but
towards neighboring helices, respectively H7 and H2 (Fig. 5).
Replacing A30 with leucine had no effect on the activity of the
three inhibitors, whereas substituting A29 with leucine strongly
impaired the activity of TAK-779 but did not affect AD101 and
SCH-C (Table 1). Hence, the predicted orientations of A29 and
A30 are likely to be accurate. The strong impairment of only
TAK-779 activity caused by the A29L substitution suggests
that this inhibitor binds differently from the other two. TAK-
779 is larger than AD101 and SCH-C, so its binding may also
depend on amino acid side chains located in the cleft between
H1 and H7.
The extracellular border of H2 contains a cluster of three
consecutive alanine residues (Fig. 5). Of these, only A90 is
oriented towards the putative binding pocket, one helical turn
above W86, a residue critical for HIV-1 entry inhibition by all
Fig. 5. Orientation of aliphatic side chains relative to the small molecule binding
site. View on the putative binding site from the extracellular side of the
membrane showing the Cα-traces of transmembrane helices H1, H2, H3 and H7
(blue-colored tubes). Key residues E283, Y37 and W86 are colored in grey with
side chain oxygen atoms labeled in red and side chain nitrogen atoms labeled in
blue. Changing the side chain size of aliphatic residues colored in red (L33, V83,
A90, G286) affected the activity of TAK-779, AD101 and SCH-C. In contrast,
substitutions of residues colored in green (A30, V40, A91, A92, A278) had no
effect on any of the three inhibitors and substitution of A29 (labeled in yellow)
by leucine only reduced the effect of HIV-1 entry inhibition by TAK-779.
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H1 and residue A92 faces outwards, away from the helical
bundle (Fig. 5). The CCR5 model suggests that replacing A90,
but not A91 or A92, with a large and bulky residue like leucine
should block the interaction with all three small molecule
inhibitors. Again, the experimental results confirm this
prediction (Table 1). As a negative control, we also included
A278 in the leucine substitution series. This residue is located
on top of H7 and predicted to point outwards, away from the
binding pocket (Fig. 5). As expected, we saw no effect of the
A278L substitution on HIV-1 entry inhibition by any of the
compounds (Table 1).
Having defined the extracellular border of the putative
binding pocket, we further explored the role of aliphatic
residues that reach deeper into the CCR5 transmembrane
domain. In particular, we were interested in L33 because this
residue, located about one helical turn above the aromatic key
residue Y37 in H1, is predicted to border the small molecule
binding pocket at the H1–H7 cleft (Fig. 5). In previous
studies (Dragic et al., 2000; Tsamis et al., 2003), it was
shown that substitution of L33 with a much smaller alanine
residue resulted in reduced sensitivity towards TAK-779,
AD101 and SCH-C (Table 1). To further explore the function
of L33, we first analyzed the effect that a polar side chain
would have at this position by replacing L33 with threonine
or asparagine. The results for the L33T and L33N mutants
indicate that a polar side chain interferes with the CCR5
interactions of TAK-779, AD101 and SCH-C (Table 1). Next,
we tested the effect of conservative amino acid changes.
Replacing L33 with either isoleucine or valine had asubstantial effect only for TAK-779 (Table 1). However,
introducing a methionine at this position reduced the
inhibitory activities of all three compounds (Table 1).
Another aliphatic residue, V40, is located about one helical
turn below Y37 and so is not directly associated with the surface
of the binding pocket (Fig. 5). Furthermore, relative to Y37 and
L33, the side chain of V40 is rotated away from the
transmembrane helical bundle. In agreement with the predic-
tions of the CCR5 model, none of the substitutions for V40
resulted in a loss of sensitivity for TAK-779, AD101 or SCH-C
(Table 1).
Similar to V40, residue V83 is also located about one helical
turn below the second key, aromatic residue W86 in H2 (Fig. 5).
In contrast to V40, however, V83 is oriented towards the
transmembrane helical bundle. Substituting V83 with alanine
resulted in a moderate reduction in sensitivity towards TAK-
779, AD101 and SCH-C (Table 1). However, more subtle
variations in the size or polarity of the side chain at residue 83
are well tolerated: replacing V83 with leucine, isoleucine, or
threonine did not result in a significantly altered response to any
of the three inhibitors (Table 1). In agreement with the CCR5
model, V83 most likely is located at the periphery of the binding
site; its interaction with the small molecule inhibitors might
involve only one of its two side chain methyl groups.
Finally, we focused our attention on residue G286, which is
located below the key acidic residue, and putative counterion,
E283 in H7. According to the CCR5 model, G286 is inside the
transmembrane helical bundle but predicted to be oriented
towards H3 and H6 rather than towards the center of the
putative binding pocket (Fig. 5). Introduction of an alanine
residue at position 286 is sufficient to inhibit the interaction
with TAK-779 (Table 1), but a considerably larger valine side
chain is required to also affect AD101 and SCH-C (Table 1). A
possible explanation for these observations would be that a
large residue at position 286 protrudes into the binding site and
interferes directly with small molecule binding. Alternatively, it
is possible that increasing the size of residue 286 perturbs the
small molecule binding site more indirectly or interferes with
the mechanism by which the binding of a small molecule
inhibits HIV-1 entry. For example, glycine residues have been
shown to be involved in helix–helix interactions in membrane
proteins (Javadpour et al., 1999; Eilers et al., 2002). Hence, it is
likely that substitution of G286 might affect the interaction of
H7 with H3 and/or H6.
Discussion
We carried out a targeted mutagenesis screen to define the
amino acid residues in CCR5 that form a ligand binding pocket
for a series of small-molecule inhibitors of cellular HIV-1 entry.
Our results indicate that side chains from residues E283, W86,
Y37, Y108, L33, V83, A90, A29 and G286 line a cavity formed
by transmembrane helices H1–H3 and H7 that is the small
molecule binding site. Furthermore, the results suggest that
E283 serves as the counterion for the positively charged
nitrogen atom common to TAK-779, AD101 and SCH-C (Fig.
1). Another key element of the putative binding pocket is a
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for the interaction of CCR5 with TAK-779, AD101 and SCH-C.
A likely scenario would be for the large indole ring of W86 to
interact with hydrophobic regions in the antagonists. However,
due to the quadrupole moment of the indole ring, interactions of
W86 with polar groups on the compounds are also possible
(Burley and Petsko, 1988).
Y37 is also involved in the interaction of CCR5 with all
three of the compounds tested. In contrast to W86, however,
the specific function of Y37 seems to be different for AD101
and SCH-C versus TAK-779. In the interaction with AD101
and SCH-C, Y37 can be replaced by any aromatic residue,
which shows that only the aromatic moiety but not the
phenolic hydroxyl group is required for this interaction. We
propose that Y37 participates in a type of interaction with
AD101 and SCH-C similar to that of W86. The interaction
with TAK-779, however, specifically requires a tyrosine at
residue 37. Hence, the phenolic hydroxyl group of Y37 may
be engaged in a specific hydrogen bond, the formation of
which is required for the inhibitory activity of TAK-779. It is
not clear whether this hydrogen bond involves TAK-779
itself, or rather another CCR5 residue. For example, the
CCR5 model predicts a potential hydrogen bond between the
hydroxyl group of Y37 and the carboxyl group of E283. It is
also not clear what role is played by the aromatic moiety of
Y37 in the interaction with TAK-779. The same conclusions
seem to apply to the involvement of Y108 in the interactions
with TAK-779 and AD101, which both require the phenolic
hydroxyl group. However, in contrast to Y37, neither the
aromatic moiety nor the hydroxyl group of Y108 is important
for the interaction with SCH-C.
Aliphatic residues of CCR5 appear to participate in
interactions with non-polar groups in the antagonists, which
could be either aromatic or aliphatic. The interaction with TAK-
779, AD101 and SCH-C was disturbed by modifications in the
polarity and/or size of the side chain at position 33. Of note is
that TAK-779 was more sensitive than AD101 and SCH-C
toward modest changes in the side chain structure, whereas all
three compounds were similarly affected by more drastic
changes. This suggests that the larger TAK-779 molecule might
be more constrained than AD101 and SCH-C within the binding
pocket. For V83, on the other hand, we could find no significant
reduction in inhibitor sensitivity upon substitution with either
polar or aliphatic side chains of similar size. However, a
moderate reduction in the inhibitory activity of TAK-779,
AD101 and SCH-C was seen when V83 was replaced with
alanine. These observations suggest that V83 might be located
at the periphery of the binding pocket where only a small
section of its side chain would interact with the antagonist
molecules—an interpretation supported by the CCR5 model.
Residues A90 and G286, which we believe define the
entrance and the bottom of the putative binding pocket,
respectively, are not likely to contribute much binding energy
because of their small side chains. However, these residues
might be important in shaping the binding pocket and providing
sufficient space for the antagonist molecules to fit into. Indeed,
substitution of A90 and G286 with large aliphatic residuesblocked the interaction of CCR5 with TAK-779, AD101 and
SCH-C. Interestingly, substituting A29, which is also at the
opening of the binding pocket but protruding into the H1–H7
cleft, affected only TAK-779 activity. Hence, TAK-779 might
extend into this cleft, a hypothesis that would also explain the
sensitivity of TAK-779 to small changes at L33.
The CCR5 model predicts that several other residues
affecting inhibitor activity are spatially separated from the
proposed binding pocket. For example, the side chains of
residues R31 and F113 face away from the binding pocket,
and residue I198 is at the opposite end of the helical bundle,
far from the putative binding pocket (Fig. 3). Changing the
identities of these residues could affect the conformation of
the small molecule binding site indirectly. Alternatively, it is
possible that the inhibitory effect of the small molecules
requires conformational changes within CCR5 and that such
changes might not occur efficiently in some of the distal site
CCR5 mutants. Substitutions at residues D76, F79 and T82,
which are located near the binding pocket (Fig. 3), could
also work in one of these indirect ways. However, it is also
possible that these residues might interact directly with
peripheral regions of the inhibitors. It is notable that D76, a
residue highly conserved among Family A GPCRs, is
believed to be involved in agonist-induced conformational
changes that lead to receptor activation (Strader et al., 1994,
1995). For example, it has been shown in a previous study
that the D76N variant has wild-type CCR5 characteristics
with regard to coreceptor activity and chemokine binding
(Farzan et al., 1997). However, chemokine binding does not
induce receptor activation in the D76N variant (Farzan et al.,
1997).
While we believe that the CCR5 residues we have identified
so far are the major interaction sites for TAK-779, AD101 and
SCH-C, there may be other, additional residues that might
constitute minor interaction sites. Such weak interactions could
have escaped detection due to the sensitivity limit of the HIV-1
entry assay or because of the limitations of the alanine
mutagenesis approach itself. Furthermore, it is possible that
hydrogen bond interactions between the peptide main chain and
the small molecule inhibitors exist. Such interactions would
remain undetected by a conventional mutagenesis approach that
necessarily focuses on the peptide side chains. Therefore, while
we have no indication for any interactions between extracellular
domain residues and TAK-779, AD101 or SCH-C, we cannot
completely rule out the possibility that some might exist.
Although the structural differences between TAK-779 and
AD101/SCH-C are substantial (Fig. 1), these inhibitors do
interact with a common set of CCR5 residues. Most likely, this
is accomplished by a set of common structural elements. The
importance of the positively charged nitrogen atoms and
hydrophobic aromatic groups, in particular, for inhibitor
effectiveness has been demonstrated by SAR studies (Shiraishi
et al., 2000; Palani et al., 2001, 2002, 2003a, 2003b; Tagat et al.,
2001a, 2001b). Furthermore, computational chemistry methods
predict that TAK-779, AD101 and SCH-C adopt a similar, bent
conformation (Fig. 3A), a structure that has been confirmed for
TAK-779 by NMR spectroscopy (data not shown). So far, it is
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change upon binding to CCR5. However, it has been shown that
four rotational isomers of SCH-C exist under physiological
conditions (Palani et al., 2001, 2003a, 2003b). These rotamers
are caused by hindered rotation at both the amide bond and the
bond linking the amide carbonyl to the unsymmetrical
nicotinamide-N-oxide (Fig. 1). Evaluation of the inhibitory
activities of the individual rotamers using both RANTES
binding and HIV-1 entry assays revealed that one was at least
10-fold more potent than the other three, indicating a clear
preference for interaction of CCR5 with this specific rotamer
(Palani et al., 2003a, 2003b).
Recently, a model for TAK-779 binding to CCR5 was
proposed based on computer docking simulations (Paterlini,
2002). This docking model agrees with some of our
experimental findings. In particular, it predicts an interaction
between E283 and the positively charged quaternary ammoni-
um group in TAK-779 (Fig. 1). Furthermore, extracellular
domain residues of CCR5 are not involved in the interaction
with TAK-779, according to the docking model. However, the
model places only the N,N-dimethyl-N-benzyl-tetrahydro-2H-
pyran-4-aminium moiety of TAK-779 (Fig. 1, right half of
TAK-779) in the pocket formed by H1, H2, H3 and H7 (Fig. 3).
The larger 4-methylphenyl-6,7-dihydro-5H-benzocyclohepte-
nyl moiety (Fig. 1, left half of TAK-779) on the other hand is
predicted to bind outside this pocket and to interact with
residues in H5 and H6. This latter prediction is not supported by
our experimental results. Thus, alanine mutagenesis identified
only a single residue, I198, in this region (Fig. 3), and mutation
of I198 affected the inhibitory activity of TAK-779 only
moderately (Dragic et al., 2000; Billick et al., 2004).
Several classes of small molecule CCR5 inhibitors have
now been described (Horuk, 2003; Schwarz and Wells, 2002;
Kazmierski et al., 2003; Maeda et al., 2004b; Seibert and
Sakmar, 2004). Comparison of the chemical structures and
available information from SAR studies does reveal common
structural elements critical for the antagonistic and antiviral
activity of these compounds. In particular, a positively
charged or basic nitrogen atom and hydrophobic aromatic
groups are key pharmacophore elements in the majority of the
CCR5 inhibitors. Hence, these might bind to CCR5 in a
fashion similar to TAK-779, AD101 and SCH-C. For
example, it was shown in a recent study that alanine-
substitution of E283, W86 and Y108 reduced the affinity of
two classes of CCR5 antagonists, 2-aryl-4(piperidin-1-yl)
butanamines and 1,2,4-trisubstituted pyrrolidines (Castonguay
et al., 2003). In contrast to TAK-779, AD101 and SCH-C,
however, substitution of Y37 with alanine did not influence
binding of these compounds to CCR5 (Castonguay et al.,
2003). The same study also showed that another aromatic
residue, Y251, is involved in the binding of the 2-aryl-4
(piperidin-1-yl)butanamines and 1,2,4-trisubstituted pyrroli-
dines (Castonguay et al., 2003). However, we could not
evaluate a possible involvement of residue Y251 in
interaction with TAK-779, AD101 and SCH-C in our studies,
because the coreceptor activity of the Y251A CCR5 variant
was too low (Dragic et al., 2000; Tsamis et al., 2003).Since chemokine receptors are structurally conserved, a
similar small molecule binding pocket may exist in other
members of this GPCR subfamily. Supporting evidence is
provided by the high degree of inter-receptor conservation
among residues that are crucial for interaction of TAK-779,
AD101 and SCH-C with CCR5. While most of these residues
are conserved within the chemokine receptor subfamily, they
are not generally conserved throughout GPCR family A
(Paterlini, 2002). For example, Y37 is conserved in all
chemokine receptors; W86 is substituted only in CCR8 and
CXCR5; E283 is substituted only in CCR7, CCR9, CXCR3 and
XCR1. Small molecule antagonists have been described for CC-
chemokine receptors CCR1 (Hesselgesser et al., 1998; Liang et
al., 2000; Naya et al., 2001b), CCR2b (Mirzadegan et al., 2000;
Forbes et al., 2000) and CCR3 (Naya et al., 2001a; Ting et al.,
2005) (see Schwarz and Wells, 2002; Carter, 2002; Horuk, 2003
for review). As with the CCR5 inhibitors, a positively charged
or basic nitrogen atom as well as aromatic groups are key
pharmacophore elements within this group of antagonists. In
particular, it has been shown that the interaction of spiropiper-
idine-based antagonists with CCR2b critically depends on the
basic nature of a specific nitrogen atom and that it requires an
acidic residue in H7 of the receptor (Mirzadegan et al., 2000).
This residue, E291, is equivalent to E283 in CCR5.
Certain antagonists of CXCR1, CXCR2, CCR2b and even
CCR5 do, however, lack a positively charged or basic nitrogen
atom (Schwarz and Wells, 2002; Carter, 2002). Such molecules
might bind to their respective receptors in a manner different
from TAK-779, AD101 and SCH-C. Yet in the case of CCR2b,
a class of acidic 2-carboxy-pyrrole antagonists was less potent
than the spiropiperidine compounds, and medicinal chemistry
optimization did not yield an antagonist useful for further
development (Mirzadegan et al., 2000). This again emphasizes
the importance of a positively charged or basic nitrogen atom
for small molecules to have potent inhibitory activity against
these various receptors.
The CXCR4 antagonist AMD3100, a symmetrical bicy-
clam, contains eight basic nitrogen atoms and is believed to
have a net charge of +4 at physiological pH (Hatse et al.,
2001). Several acidic residues in H4, H6 and H7 of CXCR4
have been shown to be involved in the interaction of
AMD3100 with the receptor (Labrosse et al., 1998; Gerlach
et al., 2001; Hatse et al., 2001; Trent et al., 2003; Rosenkilde
et al., 2003), including E288, which is the homologue of
E283 in CCR5 (Trent et al., 2003; Rosenkilde et al., 2003).
AMD3100 is believed to bind to a pocket formed by H4, H5,
H6 and H7, which is different from the small molecule
binding pocket in CCR5 (Gerlach et al., 2001; Hatse et al.,
2001; Trent et al., 2003; Rosenkilde et al., 2003). AMD3100
presumably represents a category of inhibitors that is unique
to CXCR4. The N-pyridinmethyl cyclam analog AMD3451
on the other hand has been shown to be a dual antagonist for
CCR5 and CXCR4 (Princen et al., 2004).
The high degree of inter-receptor conservation among
residues that are crucial for interaction of CCR5 with small
molecule inhibitors raises the question of how the receptor
specificity of these compounds is achieved. TAK-779, for
50 C. Seibert et al. / Virology 349 (2006) 41–54example, is an antagonist for CCR5 and CCR2b but has no
effect on other chemokine receptors (Baba et al., 1999).
AD101 and SCH-C on the other hand are highly specific for
CCR5, although there is some very low residual potency for
muscarinic receptors (Tagat et al., 2001b; Palani et al., 2001;
Strizki et al., 2001). Our results suggest that common
structural elements within the small molecules interact with
the conserved residues in the chemokine receptors. Selectivity
could then be provided by additional interactions involving
more specific small molecule elements and variable chemo-
kine receptor residues. Although sequence diversity among
chemokine receptors is most pronounced within the extracel-
lular domain, we could find no evidence for any involvement
of this region in small molecule interactions. Thus, it is most
likely that relatively subtle variations in transmembrane
domain residues account for receptor specificity. Less-
conserved residues could directly interact with inhibitors,
increasing affinity by providing additional contacts or
decreasing it due to steric hindrance. Alternatively, variable
residues could indirectly influence the conformation of the
binding pocket and hence the precise positions of other
functionally important amino acid side chains.
AD101 and SCH-C were developed from early lead
compounds that are potent antagonists for the M2 muscarinic
receptor (Tagat et al., 2001a, 2001b; Palani et al., 2001,
2002). The M2 receptor does not possess an acidic residue in
H7 that is equivalent to E283 in CCR5. However, an acidic
residue in H3 serves as the counterion for positively charged
nitrogen atoms in agonists and antagonists of muscarinic and
other biogenic amine receptors (Fraser et al., 1989; Strader et
al., 1995). Our results show that the precise location of the
E283 carboxyl group in CCR5 is critical for inhibitor activity
(Fig. 4). In particular, swapping the glutamate residue from
H7 to H3 on the opposite side of the binding pocket is not
tolerated. Hence, we believe that, in the optimization process
creating AD101 and SCH-C, structural modifications were
introduced into the inhibitors that favor the use of a
counterion in H7 over a counterion in H3. For example, it
has been shown that the specificity of AD101-related
compounds is controlled in part by the stereochemistry of
the piperazine 2-methyl substituent, which is in the vicinity of
the protonated nitrogen atom (Fig. 1): the 2(S)-configuration
favors an interaction with CCR5 while the 2(R)-configuration
results in M2 antagonists (Tagat et al., 2001a, 2001b). Thus, it
seems possible that the piperazine 2-methyl group influences
receptor specificity by directing the protonated nitrogen atom
towards either H3 or H7.
TAK-779, AD101 and SCH-C most likely prevent the
cellular entry of HIV-1 by inhibiting the interaction of gp120
with CCR5 subsequent to CD4 binding (Dragic et al., 2000;
Tsamis et al., 2003). The precise nature of the gp120-CCR5
interaction is not clear; however, available evidence indicates
that the N-terminus of CCR5 interacts with residues in the
β19 strand and near the base of V3, while the V3 crown may
interact with ECL2 residues (Cormier and Dragic, 2002;
Hartley et al., 2005). How inhibition occurs is not well
understood on a molecular level. One possibility is that smallmolecule binding to the transmembrane domain of CCR5
selectively stabilizes or induces a receptor conformation that
is not recognized by gp120 (Dragic et al., 2000; Tsamis et al.,
2003; Kazmierski et al., 2003; Kenakin, 2004). Alternatively,
the small molecules might compete directly with gp120 due
to a partial overlap between their respective binding sites.
Although we cannot completely rule out the latter alternative,
we believe that the experimental evidence favors an allosteric
mechanism. In particular, we could find no evidence for any
interaction of TAK-779, AD101 or SCH-C with the
extracellular domain of CCR5 (Dragic et al., 2000; Tsamis
et al., 2003); gp120 on the other hand has been shown to
interact predominantly with residues in this receptor region
(Rucker et al., 1996; Ross et al., 1998; Blanpain et al., 1999;
Howard et al., 1999; Dragic, 2001; Dragic et al., 1998; Rabut
et al., 1998; Farzan et al., 1998; Doranz et al., 1997).
Furthermore, it was shown that AD101 and SCH-C both
inhibit the binding of several monoclonal antibodies that
recognize conformational epitopes in E2 of CCR5 (Tsamis et
al., 2003). This observation is most simply explained by the
binding of AD101 and SCH-C causing conformational
changes in CCR5 that alter the conformation of the antibody
epitopes. These changes would also affect regions of the
receptor known to interact with gp120 (Tsamis et al., 2003).
TAK-779, AD101 and SCH-C not only inhibit HIV-1 entry,
they also act as classical GPCR antagonists by blocking
chemokine binding to CCR5 (Baba et al., 1999; Palani et al.,
2001, 2002; Tagat et al., 2001a; Strizki et al., 2001). Although
the primary chemokine binding site in the extracellular domain
of CCR5 seems to have no overlap with the small molecule
binding site, there is evidence for a secondary chemokine
interaction site in the transmembrane domain of CCR5
(Blanpain et al., 2003). This site is likely to overlap with the
small molecule binding site, allowing for a direct competition
between the small molecules and the chemokines. However, it
has been shown that chemokine interaction with this secondary
site is required only for receptor activation, and not for
chemokine binding (Blanpain et al., 2003). We therefore
believe that an allosteric mechanism similar to the one proposed
above for the inhibition of the gp120 interaction agrees better
with the experimental evidence than does a direct competition
mechanism. The allosteric receptor inhibition model is
supported by the results from chemokine binding competition
studies with a panel of five CCR5 antagonists including TAK-
779, SCH-C, SCH-D, UK-427,857 and GSK-873140 (formerly
AK602) (Watson et al., 2005). These results indicate that all five
antagonists bind to a common allosteric site on CCR5 and that
they interfere with chemokine receptor interaction in a non-
competitive fashion.
While TAK-779, AD101 and SCH-C completely block both
HIV-1 entry and chemokine binding, certain other small
molecules with differential effects have been described. For
example, GSK-873140 has been shown to completely block
HIV-1 entry; however, this compound is only a partial
antagonist of chemokine binding (Maeda et al., 2004a; Watson
et al., 2005). Furthermore, differential effects of certain CCR5
inhibitors are also implied by differences in their ability to block
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2004a; Dragic et al., 2000; Tsamis et al., 2003). Within the
framework of the allosteric receptor inhibition model (Kenakin,
2004, 2005), these differential effects can be explained by the
conformational flexibility of GPCRs. While relatively subtle
differences in the overall shape of the inhibitors or the presence
of certain peripheral groups may not have a strong effect on the
receptor affinity, such specific features might be crucial for
inducing slightly different receptor conformations leading to
different allosteric effects. For example, extensive SAR studies
performed on 2-aryl-4(piperidine-1-yl)butanamines and 1,2,4-
trisubstituted pyrrolidines revealed structural features that are
selectively required for inhibition of HIV-1 entry but not for
chemokine antagonism (see Seibert and Sakmar, 2004 for
review).
Significance
We have identified CCR5 amino acid residues that are
critical for three separate small molecule antagonists, TAK-779,
AD101 or SCH-C, to interact efficiently with CCR5 to inhibit
HIV-1 entry. The antagonists, which were the result of targeted
drug discovery programs, bind to similar but not completely
identical sites on CCR5. We found no evidence for any
interaction of TAK-779, AD101 or SCH-C with extracellular
domain residues. A homology model of CCR5 predicts that the
majority of the residues identified to be important line a cavity
formed by transmembrane helices H1, H2, H3 and H7. Hence,
we conclude that this cavity is the small molecule binding
pocket. Within this putative binding pocket, residues E283,
W86, Y37, Y108, L33, V83, A90, A29 and G286 are well
positioned to interact with a bound antagonist. This is the first
study to report a side-by-side comparison of multiple drug
candidates using a functional assay of HIV-1 entry with the aim
of defining the ligand binding site on the CCR5 coreceptor. Our
results provide a structural basis for understanding how the
binding of small molecules leads to inhibition of the HIV-1
coreceptor and chemokine receptor functions of CCR5.
Understanding how small molecule inhibitors interact with
CCR5 might facilitate the rational design of improved CCR5
antagonists with activity against HIV-1 entry, and also against
inflammatory and autoimmune diseases in which CCR5 is also
implicated (Yang et al., 2002). In addition, this work provides a
framework for understanding how rare, single amino acid
polymorphisms of CCR5 might influence the antiviral
responses of HIV-1-infected individuals to therapy with
compounds like SCH-C and its derivatives. The eventual
emergence of HIV-1 resistance to CCR5 antagonist therapies
might also be better understood by knowledge of how the drugs
interact with CCR5.
Materials and methods
Compounds
TAK-779 (N,N-dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-
dihydro-5H-benzocyclohepten-8-yl]carbonyl]amino]benzyl]tetrahydro-2H-pyran-4-aminium chloride; Mr = 531.13) was
obtained from the AIDS Research and Reference Reagent
Program, NIAID, NIH, contributed by DAIDS (Baba et al.,
1999; Dragic et al., 2000). AD101 (SCH-350581) (1-[(2,4-
Dimethyl-3-pyridinyl)carbonyl]-4-methyl-4-[3(S)-methyl-4-[1
(S)-[4-(trifluoro-methyl)phenyl]ethyl]-1-piperazinyl]-piperi-
dine; Mr = 502.62) and SCH-C (SCH-351125) (4-[(Z)-(4-
Bromophenyl)(ethoxyimino)methyl]-1′-[(2,4-dimethyl-3-pyri-
dinyl)carbonyl]-4′-methyl-1,4′-bipiperidine N-oxide;
Mr = 557.53) were synthesized as described (Palani et al.,
2001, 2002; Tagat et al., 2001b). The chemical structures of
these compounds are depicted in Fig. 1.
Energy-minimized structures of CCR5 inhibitors
Energy-minimized structures of TAK-779 (including chlo-
ride counterion), AD101 and SCH-C were calculated using the
PM3 semi-empirical method of the HyperChem software
(Hypercube Inc., Gainesville, FL).
Structural model of the transmembrane domain of CCR5
The crystal structure of bovine rhodopsin (PDB ID 1F88)
(Palczewski et al., 2000) was used as a template to model
the transmembrane domain of CCR5. The amino acid
sequence of CCR5 was aligned with that of rhodopsin. The
CCR5 amino acid side chains were extended from the
helical backbone of the rhodopsin structure and energy-
minimized with the program X-PLOR (Brunger, 1992),
using Powell minimization for 10,000 cycles. Hydrogen-
bonding restraints were applied between the backbone amide
and carbonyl groups. This allowed the transmembrane
helices (H1–H7) to maintain α-helical structure, but
provided flexibility for kinks to be introduced at transmem-
brane prolines unique to CCR5. Hydrogen-bonding restraints
were also applied between the following pairs of residues:
N48-D76, N71-W153, Y214-R235, D125-R126 and N293-
Y297. These residues generally are conserved in GPCRs
and are thought to form key intramolecular interactions. The
model predicts a large number of hydrogen-bonding
interactions including Y37-E283 and D76-H289. The
following residues are included in the CCR5 structural
model: H1 (K26-C58), H2 (S63-W94), H3 (F96-V131), H4
(T141-I165), H5 (W190-I217), H6 (K228-Q261) and H7
(L275-G301). Molecular graphics were prepared using the
program DINO (Visualizing Structural Biology (2002),
http://www.dino3d.org).
Site-directed mutagenesis of CCR5
A pcDNA3.1 (Invitrogen, Carlsbad, CA)-based expression
plasmid was used as the template for site-directed mutagen-
esis of CCR5. This plasmid contains the coding sequence for
a CCR5 construct with a C-terminal hemagglutinin affinity
tag (Dragic et al., 1998). Site-directed mutagenesis was
performed using the QuickChange method (Stratagene, La
Jolla, CA) and mutations were verified by DNA sequencing
52 C. Seibert et al. / Virology 349 (2006) 41–54of the entire CCR5-coding region (The Rockefeller University
Protein/DNA Technology Center, New York).
HIV-1 entry assay
Human astroglioma cells stably expressing CD4 (U87-CD4
cells) were transfected with expression plasmids encoding wild-
type or mutant CCR5 using either Lipofectin or Lipofect-
AMINE 2000 (Invitrogen, Carlsbad, CA) (Dragic et al., 1998).
Entry of HIV-1 reporter virus (NLenv−luc+ virus) pseudotyped
with envelope glycoproteins (Env) from the HIV-1 JR-FL
isolate and bearing the firefly luciferase gene into the
transfected U87-CD4 cells was determined by quantifying
luciferase expression, as previously described (Dragic et al.,
1998). The luciferase activity was directly proportional to viral
entry, as confirmed by serial dilution of the virus in the absence
of inhibitors (data not shown).
Effect of inhibitors on HIV-1 entry
For each CCR5 mutant HIV-1 entry, experiments were
performed in the presence of 200 nM TAK-779, 100 nMAD101
or 100 nM SCH-C, and in the absence of any inhibitor. To
evaluate the sensitivity of the CCR5 mutants to these inhibitors,
relative entry levels were calculated as described elsewhere
(Dragic et al., 2000): a value of 100% viral entry in the presence
of an inhibitor means that a mutant is completely insensitive to
the inhibitor. Conversely, a value of 0% viral entry in the
presence of an inhibitor means that a mutant is as sensitive to the
inhibitor as wild-type CCR5. Mean entry levels and standard
errors were calculated from the results of at least three
independent experiments with quadruplicate samples. Based
on statistical parameters of the entry assay, it was estimated that
mutants yielding ≥14% viral entry in the presence of an
inhibitor have a significantly reduced sensitivity for the
respective inhibitor (Dragic et al., 2000). CCR5 substitutions
that affect HIV-1 entry also affect the sensitivity of the entry
assay in the presence of an inhibitor. Thus, a few mutants,
apparently more sensitive to inhibition than wild-type CCR5,
yielded entry levels b0%. These effects were small and may
have no functional implications. For clarity, values b0% are
represented as = 0%. In the absence of inhibitors, the different
CCR5 mutants supported 7–130% of the entry level for wild-
type CCR5.
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